QDEL - Quidel Corporation

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
79.86
-0.54 (-0.67%)
At close: 4:00PM EST

79.58 -0.28 (-0.36%)
After hours: 4:11PM EST

Stock chart is not supported by your current browser
Previous Close80.40
Open79.91
Bid55.01 x 800
Ask79.92 x 1300
Day's Range78.56 - 80.21
52 Week Range52.49 - 81.99
Volume168,155
Avg. Volume225,542
Market Cap3.251B
Beta (5Y Monthly)1.40
PE Ratio (TTM)44.47
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
Press Releases
  • Business Wire

    Quidel to Present at Upcoming Conferences

    Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it will present at the following upcoming conferences:

  • Business Wire

    Quidel Reports Fourth Quarter and Full Year 2019 Financial Results

    Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today financial results for the fourth quarter and the year ended December 31, 2019.

  • Business Wire

    Quidel to Hold Fourth Quarter and Full Year 2019 Financial Results Conference Call on February 12th, 2020

    Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, will report fourth quarter and full year 2019 financial results after market close on Wednesday, February 12, 2020.

  • Business Wire

    Quidel Announces Preliminary Revenue for Fourth Quarter 2019

    Quidel Corporation (NASDAQ: QDEL) ("Quidel"), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it expects revenues in the fourth quarter of 2019 to be in the range of $151 million to $152 million.

  • Business Wire

    Quidel Receives 510(k) Clearance for Quidel Triage® TOX Drug Screen, 94600 Toxicology Test for Use With Quidel’s Triage® MeterPro Instrumented System

    Quidel Corporation (QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Quidel has received 510(k) clearance from the Unites States Food and Drug Administration (FDA) to market the Quidel Triage® TOX Drug Screen, 94600, a fluorescence immunoassay for the qualitative determination of the presence of drug and/or metabolites in human urine of up to 9 drug assays. The test is to be used with Quidel’s Triage® MeterPro instrumented system.

  • Business Wire

    Quidel Announces Private Exchange Transactions

    Quidel Corporation (QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it has entered into separate, privately negotiated exchange agreements with certain holders of its 3.25% Convertible Senior Notes due 2020 (the “2020 Notes”). Pursuant to these exchange agreements Quidel will exchange approximately $45.372 million in aggregate principal amount of the 2020 Notes for (i) approximately 1,273,601 shares of the company’s common stock plus (ii) an additional number of newly issued shares of the company’s common stock to be determined based on the volume weighted average price of the company’s common stock over the three consecutive trading days commencing on June 5, 2019.

  • Business Wire

    Quidel to Present at William Blair 39th Annual Growth Stock Conference

    Quidel Corporation (QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it will present at the William Blair 39th Annual Growth Stock Conference at the Loews Chicago hotel in Chicago, Illinois on Thursday, June 6, 2019. Randy Steward, chief financial officer, will present on Thursday, June 6, 2019 at 1:20 p.m. Central Time (11:20 a.m. Pacific Time) with a question-and-answer session scheduled immediately following the presentation. Participants should allow approximately five to ten minutes prior to the presentation's start time to visit the site and download any streaming media software needed to listen to the Internet webcast.

  • Business Wire

    Quidel Reports First Quarter 2019 Financial Results

    Quidel Corporation , a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today financial results for the first quarter ended March 31, 2019.

  • Business Wire

    Quidel to Present at the Bank of America Merrill Lynch Health Care Conference 2019

    Quidel Corporation , a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it will present at the Bank of America Merrill Lynch Health Care Conference 2019, to be held at the Encore at Wynn hotel in Las Vegas, Nevada on Thursday, May 16, 2019.

  • Business Wire

    Quidel to Hold First Quarter 2019 Financial Results Conference Call on May 8th, 2019

    Quidel Corporation (QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, will report first quarter 2019 financial results after market close on Wednesday, May 8, 2019. Following the release of results, Douglas Bryant, president and chief executive officer, and Randy Steward, chief financial officer, will host an investment community conference call beginning at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) to discuss the results and answer questions.